Atenolol — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Hypertension

• Amlodipine
• Bisoprolol
• Carvedilol
• Diltiazem
• Furosemide
• Hydrochlorothiazide
• Lisinopril
• Losartan

Other medications in Heart & Cardiovascular

• Atorvastatin
• Azilsartan
• Bempedoic Acid
• Benazepril
• Bosentan
• Bumetanide
• Candesartan
• Cangrelor

About Atenolol

Atenolol is a widely prescribed beta-blocker crucial for managing various heart conditions like high blood pressure and angina. Understanding its role in your health is important, and with TheDrugClub, accessing this vital medication is not only easy but also incredibly affordable, helping you save significantly on your prescription costs.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Atenolol is approved for (FDA label)

Hypertension Atenolol tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals.

Source: Read the full FDA label on DailyMed. Label effective date: September 3, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Atenolol (FDA label)

Most adverse effects have been mild and transient. The frequency estimates in the following table were derived from controlled studies in hypertensive patients in which adverse reactions were either volunteered by the patient (US studies) or elicited, e.g., by checklist (foreign studies). The reported frequency of elicited adverse effects was higher for both atenolol and placebo-treated patients than when these reactions were volunteered. Where frequency of adverse effects of atenolol and placebo is similar, causal relationship to atenolol is uncertain.

Source: FDA prescribing information (DailyMed). Set ID: 897e18f6-3b57-4ef0-85ff-9dfa23521eb9. SPL document ID: 5a958fd9-d675-701c-e063-6394a90a9a13. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Atenolol (FDA label)

Atenolol tablets are contraindicated in sinus bradycardia, heart block greater than first degree, cardiogenic shock, and overt cardiac failure. (See WARNINGS .) Atenolol tablets are contraindicated in those patients with a history of hypersensitivity to the atenolol or any of the drug product's components.

Source: FDA prescribing information (DailyMed). Set ID: 897e18f6-3b57-4ef0-85ff-9dfa23521eb9. SPL document ID: 5a958fd9-d675-701c-e063-6394a90a9a13. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Atenolol (FDA label)

Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. Patients treated with atenolol plus a catecholamine depletor should therefore be closely observed for evidence of hypotension and/or marked bradycardia which may produce vertigo, syncope, or postural hypotension. Calcium channel blockers may also have an additive effect when given with atenolol (see WARNINGS ). Disopyramide is a Type I antiarrhythmic drug with potent negative inotropic and chronotropic effects. Disopyramide has been associated with severe bradycardia, asystole and heart failure when administered with beta-blockers. Amiodarone is an antiarrhythmic agent with negative chronotropic properties that may be additive to those seen with beta-blockers. Beta-blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine. If the two drugs are coadministered, the beta-blocker should be withdrawn several days before the gradual withdrawal of clonidine.

Source: FDA prescribing information (DailyMed). Set ID: 897e18f6-3b57-4ef0-85ff-9dfa23521eb9. SPL document ID: 5a958fd9-d675-701c-e063-6394a90a9a13. Label effective date: September 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.